HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to stall return of head and neck cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to precise, high-dose radiation (SBRT) can help people with head and neck cancer that has returned or is a new tumor in the same area. About 86 adults whose cancer cannot be removed by surgery will be…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2 • Sponsor: RTOG Foundation, Inc. • Aim: Disease control
Last updated May 26, 2026 05:04 UTC
-
New drug AB598 takes first steps against advanced cancers
Disease control OngoingThis early-phase study tests a new drug called AB598, alone or with other treatments, in about 40 people with advanced solid tumors like lung, bladder, or ovarian cancer. The main goal is to check if the drug is safe and tolerable. Participants must have measurable tumors and be …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated May 26, 2026 05:02 UTC
-
New drug cocktail aims to shrink Hard-to-Treat head and neck tumors
Disease control OngoingThis study tests whether adding an experimental drug (INBRX-106) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with advanced head and neck cancer that has spread or come back. About 410 adults whose tumors have a specific marker (PD-L1…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2, PHASE3 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated May 26, 2026 05:00 UTC
-
New drug cocktail aims to shrink head and neck tumors before surgery
Disease control OngoingThis study tests whether adding another immune-boosting drug (relatlimab or ipilimumab) to the standard immunotherapy nivolumab can better shrink head and neck tumors before surgery. About 80 adults with advanced but removable head and neck cancer will receive one of these combin…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New drug cocktail shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether combining several drugs can shrink tumors in adults with head and neck cancer that has returned or spread, and where prior treatments have failed. Participants receive a mix of antibodies that boost the immune system, block tumor growth signals, and cut o…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New antibody combo shows promise against tough cancers
Disease control OngoingThis study tests an experimental antibody called GEN1042, alone or with the cancer drug pembrolizumab (with or without chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The goal is to see if the treatment is safe …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated May 07, 2026 18:38 UTC
-
Scientists hunt for clues to predict who benefits from head and neck cancer immunotherapy
Knowledge-focused OngoingThis study aims to find immune-related markers in blood and tumor tissue that can predict how well patients with recurrent or metastatic head and neck cancer respond to the drug nivolumab. Researchers will analyze samples from 50 adults who have already tried platinum chemotherap…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: NA • Sponsor: Yonsei University • Aim: Knowledge-focused
Last updated May 26, 2026 05:03 UTC